These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Stunning after tracer dosimetry. Diehl M; Grünwald F J Nucl Med; 2001 Jul; 42(7):1129. PubMed ID: 11438639 [No Abstract] [Full Text] [Related]
5. [Stunning effects in radioiodine therapy of thyroid carcinoma: existence, clinical effects and ways out]. Koch W; Knesewitsch P; Tatsch K; Hahn K Nuklearmedizin; 2003 Feb; 42(1):10-4. PubMed ID: 12601448 [TBL] [Abstract][Full Text] [Related]
6. Partial stunning in thyroid remnant after administration of scanning dose followed by 100 mCi I-131 therapy. Yagcloglu H; Ozalp E; Ibis E; Aras G Clin Nucl Med; 1996 Apr; 21(4):340. PubMed ID: 8925630 [No Abstract] [Full Text] [Related]
7. Whole-body scanning with radionuclides of iodine, and the controversy of "thyroid stunning". Kalinyak JE; McDougall IR Nucl Med Commun; 2004 Sep; 25(9):883-9. PubMed ID: 15319592 [No Abstract] [Full Text] [Related]
8. Anti-thyroglobulin antibodies and risk of finding iodine avid metastases on post-radioactive iodine ablation scan in low-risk thyroid cancer patients. Rosario PW J Endocrinol Invest; 2017 Sep; 40(9):1023. PubMed ID: 28569364 [No Abstract] [Full Text] [Related]
9. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer. Gerard SK; Dam HQ Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947 [No Abstract] [Full Text] [Related]
10. Radioiodine and thyroid cancer: some questions, controversies, and considerations. Daniels GH Endocr Pract; 2001; 7(4):320-3. PubMed ID: 11497485 [No Abstract] [Full Text] [Related]
11. New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Hoefnagel CA; Delprat CC; Zanin D; van der Schoot JB Clin Nucl Med; 1988 Mar; 13(3):159-65. PubMed ID: 2838213 [TBL] [Abstract][Full Text] [Related]
12. Nuclear medicine and thyroid cancer. Jana S; Abdel-Dayem HM; Young I Eur J Nucl Med; 1999 Dec; 26(12):1528-32. PubMed ID: 10638402 [No Abstract] [Full Text] [Related]
13. Radioiodine in treatment of metastatic thyroid cancer. Dewan SS; Sharma SM; Ganatra RD Int J Nucl Med Biol; 1979; 6(4):213-4. PubMed ID: 528148 [No Abstract] [Full Text] [Related]
14. 123I imaging in the follow-up of differentiated thyroid cancer. Fenwick JD; Mallick UK; Perros P Clin Oncol (R Coll Radiol); 2001; 13(4):314. PubMed ID: 11554639 [No Abstract] [Full Text] [Related]
16. Artifactual I-131 activity in the hairs after thyroid remnant ablation. Bhargava P; Choi WS Thyroid; 2006 Nov; 16(11):1187-9. PubMed ID: 17123350 [No Abstract] [Full Text] [Related]
17. Contamination of a bracelet following iodine-131 therapy: a case report. Bybel B; Beebe W; Kim BY; Faiman C J Nucl Med Technol; 2000 Dec; 28(4):257-8. PubMed ID: 11142327 [TBL] [Abstract][Full Text] [Related]
18. [The autonomous thyroid nodule: results of treatment with radioiodine]. Schachter D; Atria A; Pineda G Rev Med Chil; 1986 Mar; 114(3):228-31. PubMed ID: 3544122 [No Abstract] [Full Text] [Related]
19. 123Imaging in the follow-up of differentiated thyroid cancer. Violet J; Nutting C; Plowman PN; Britton KE Clin Oncol (R Coll Radiol); 2001; 13(4):313-4. PubMed ID: 11554638 [No Abstract] [Full Text] [Related]
20. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. Morris LF; Waxman AD; Braunstein GD J Clin Endocrinol Metab; 2001 Aug; 86(8):3507-11. PubMed ID: 11502771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]